Does hepatic insulin resistance increase VLDL output and drive atherogenic dyslipidemia?

Hepatic insulin resistance is a primary driver of metabolic dysregulation, directly altering the liver's production of lipoproteins and reshaping the systemic lipid profile toward a highly atherogenic state.

Mechanistic basis for VLDL overproduction

In a healthy state, insulin regulates hepatic lipid metabolism by suppressing the assembly and secretion of very-low-density lipoprotein (VLDL) particles. It achieves this by promoting the degradation of apolipoprotein B (apoB) and inhibiting the transcription of microsomal triglyceride transfer protein (MTP).

• Selective Resistance: In hepatic insulin resistance, these inhibitory signals fail. The liver loses its ability to suppress MTP, while paradoxically maintaining or increasing de novo lipogenesis via the SREBP-1c pathway.
• Substrate Availability: This creates a "perfect storm" where high levels of triglyceride substrates are combined with unregulated MTP activity, leading to a significant increase in the secretion of large, triglyceride-rich VLDL1 particles.

Development of atherogenic dyslipidemia

The overproduction of VLDL initiates a cascade of remodeling in the bloodstream that results in a specific lipid phenotype.

• LDL Remodeling: High levels of circulating VLDL trigger the exchange of triglycerides for cholesterol esters in LDL particles, a process mediated by cholesteryl ester transfer protein (CETP).
• Formation of sdLDL: These triglyceride-enriched LDL particles are then hydrolyzed by hepatic lipase. This process strips the particles of their core lipids, resulting in smaller, denser LDL (sdLDL) particles with a significantly reduced peak diameter.
• Increased Particle Number (LDL-P): Because these sdLDL particles are cholesterol-poor, a higher total number of particles (LDL-P) is required to carry a given concentration of LDL cholesterol. Human tracer studies and clinical assays consistently show that insulin-resistant individuals exhibit elevated LDL-P and apolipoprotein B levels, even when total LDL cholesterol remains within standard reference ranges.

Bottom line

Hepatic insulin resistance drives a shift toward an atherogenic lipid profile by increasing VLDL output and promoting the formation of small, dense LDL particles and higher particle counts. This metabolic environment significantly elevates cardiovascular risk by increasing the number of particles capable of penetrating the arterial wall.